Necrotic Lung Cancer: Insights on Pathophysiology & Treatments

Detailed diagram of lung cancer necrosis

Intro

Necrotic lung cancer represents a complex interplay of cellular mechanisms and external factors that pose significant challenges for both diagnosis and treatment. This subtype of lung cancer is characterized by the presence of necrotic tissue within tumors, which can influence tumor behavior and patient prognosis. Understanding the nuances of this condition is crucial for medical practitioners, researchers, and students alike, as it sheds light on current therapeutic approaches and future research trends.

The impact of necrosis in tumor biology cannot be overstated. When cells die within a tumor, it can lead to a range of complications including inflammation, immune response modulation, and changes in tumor microenvironment. These elements create a unique set of challenges that diverge from typical lung cancer presentations. Current research trends focus on unraveling these mechanisms to optimize diagnosis and develop more effective treatments.

Engaging with this topic provides insights not just into necrotic lung cancer itself, but also the broader implications within oncology. By examining the pathophysiology, treatment challenges, and evolving therapeutic strategies, this article aims to serve as a comprehensive guide for those looking to deepen their understanding of this pressing medical issue.

Intro to Necrotic Lung Cancer

Necrotic lung cancer is a term that refers to a specific subset of lung tumors characterized by the presence of necrosis within the tumor mass. Understanding this condition is crucial, as necrosis can significantly influence tumor behavior, response to treatment, and overall patient outcomes. The complexity of this pathology mandates a careful examination of its mechanisms, as well as the unique challenges it poses in diagnosis and management.

One important aspect of necrotic lung cancer is that it can complicate tumor identification and staging. Necrotic tissues often mask the true extent of disease during imaging studies, leading to potential underestimations or misinterpretations. For healthcare professionals, recognizing the presence of necrosis is vital to tailoring appropriate treatment strategies.

Research into necrotic lung cancer extends beyond merely identifying and treating it. Investigating the mechanisms that lead to necrosis contributes to a broader understanding of tumor biology. This knowledge can foster the development of innovative therapies aimed at targeting specific pathways involved in tumor cell death and survival.

Ultimately, gaining insights into necrotic lung cancer is beneficial for both practitioners and patients. As oncological research continues to evolve, the integration of this knowledge into clinical practice will play a significant role in enhancing patient care.

Defining Necrotic Lung Cancer

Necrotic lung cancer is defined primarily by the presence of necrosis—the death of tissue—within malignant lung tumors. This necrosis can arise due to various factors, including inadequate blood supply to the tumor, resulting from its rapid growth. As cells die, they release cellular debris, contributing to inflammation and potentially altering immune response.

The significance of necrosis goes beyond histological observation. The necrotic areas can influence the tumor microenvironment, impacting surrounding tissues and systemic responses. Thus, the mere presence of necrosis serves as both a marker and a modifying factor in lung cancer progression.

Studies indicate that the extent of necrosis may correlate with the aggressiveness of the tumor and its propensity to metastasize. Furthermore, it interferes with the typical responses to treatments like chemotherapy or radiotherapy. Necrotic tumors may require alternative therapeutic approaches, which highlights the necessity of accurate diagnosis.

Relevance in Oncological Research

The study of necrotic lung cancer is highly relevant within the field of oncological research. Understanding the mechanisms of necrosis can assist in unraveling the intricate interplay between tumor growth and host responses. Researchers aim to identify biomarkers associated with necrotic tissues, which could help in predicting treatment outcomes.

Moreover, research on targeted therapies is increasingly focusing on exploiting the unique characteristics of necrotic tumors. By identifying metabolic byproducts produced in necrosis, therapeutics could potentially be designed to minimize the adverse effects of the condition, enhancing patient prognosis.

As the landscape of cancer treatment continues to evolve, the insights gained from studying necrotic lung cancer are pivotal. They guide the development of more effective interventions, shaping therapeutic paradigms that are customized to the individual patient.

"The exploration of necrezotic processes in tumors allows us to refine our understanding of cancer behavior and treatment efficacy."

By examining these dynamics further, oncology researchers aim to pave new paths in personalized treatment, ultimately contributing to improved patient care and outcomes.

Pathophysiology of Necrosis in Lung Cancer

The pathophysiology of necrosis in lung cancer is a critical aspect that informs both the understanding of tumor dynamics and the formulation of treatment strategies. As the tumor grows and outgrows its blood supply, central areas may not receive adequate oxygen, leading to necrosis. The importance of the pathophysiology lies in its implications for prognosis and therapeutic approaches. Understanding the mechanisms that lead to necrosis can help in identifying potential therapeutic targets and improving patient outcomes.

Mechanisms Leading to Tumor Necrosis

The primary mechanism behind necrosis in lung tumors is hypoxia, a condition where the oxygen supply becomes insufficient for cellular metabolism. When tumor cells proliferate rapidly, they can create a dense environment that constricts their own blood supply. Other factors contributing to necrosis include:

Tumor Size: Larger tumors are more likely to experience necrosis as they can outgrow their vascular supply.
Vascular Aberrations: Tumors often develop irregular blood vessels that are leaky or poorly formed, resulting in inefficient blood flow.
Metabolic Demand: Increased metabolic activities of cancer cells exceed available oxygen and nutrients, leading to cell death.

These necrotic regions can trigger a cascade of inflammatory responses, further complicating the tumor environment and presenting new challenges for treatment.

Cellular and Molecular Changes

As necrosis occurs in lung cancer, significant cellular and molecular changes take place. The necrotic process influences not just the tumor itself but also the surrounding tissues and the immune system. Key changes include:

Release of Damage-Associated Molecular Patterns (DAMPs): Necrotic cells release signals that can provoke an immune response. While this can be beneficial, it may also lead to chronic inflammation, aiding tumor progression.
Altered Cell Signaling: The presence of necrotic tissue alters the tumor microenvironment, affecting signaling pathways. Such changes can influence growth factor availability and contribute to the aggressiveness of the cancer.
Metabolite Accumulation: Accumulation of metabolites in necrotic areas can change the pH and environment, which further affects cellular behavior and treatment response.

These changes highlight the complexity of necrotic lung cancer and emphasize the need for research focused on these biological processes. Understanding these alterations can guide the development of more effective treatments that consider the unique environment of necrotic tumors.

Graphical representation of tumor behavior changes due to necrosis

Clinical Implications of Necrotic Lung Cancer

Understanding the clinical implications of necrotic lung cancer is crucial for both practitioners and researchers. This section delves into the significance of accurate diagnosis and timely intervention. The implications stretch across areas like patient management, treatment efficacy, and overall prognosis. With necrotic tumors exhibiting distinct behavior compared to non-necrotic counterparts, identifying these traits influences treatment decisions.

Diagnosis of Necrotic Lung Tumors

Imaging Techniques

Imaging techniques play a critical role in diagnosing necrotic lung tumors. Common methods include computed tomography (CT) scans and magnetic resonance imaging (MRI). A key characteristic of CT scans is their ability to provide detailed cross-sectional views of lung structures, revealing necrotic areas within tumors effectively. This detail is important because necrosis can indicate tumor aggressiveness.

Advantages of CT scans include quick acquisition of images and widespread availability. However, there are some disadvantages. For instance, exposure to radiation is a concern, especially in younger patients. MRI, while offering superb soft tissue contrast, is less commonly used due to longer scanning times and availability.

Histopathological Evaluation

Histopathological evaluation focuses on analyzing tumor specimens under a microscope. This method reveals cellular characteristics indicative of necrosis, such as changes in cell architecture and cellular debris. A notable feature of histopathological analysis is its accuracy in distinguishing necrotic tumors from other types. This is a significant benefit when devising treatment plans.

A unique aspect of this evaluation is the ability to assess the tumor microenvironment. However, histopathology requires tissue samples, which can be obtained through biopsies that might carry some procedural risks. Software enhancements for immunohistochemistry streamline the processing and analysis of samples but can add complexity.

Symptoms and Signs

Recognizing the symptoms and signs of necrotic lung cancer is vital for early detection and treatment. Patients may present with various respiratory symptoms, including chronic cough, chest pain, and hemoptysis. Additionally, systemic symptoms like weight loss and fatigue may signal disease advancement.

Vigilance in observing these symptoms can lead to timely intervention, which could optimize patient outcomes. Early diagnosis often correlates with improved survival rates, making this aspect of clinical practice particularly significant.

"Timely diagnosis and tailored treatment strategies can significantly change the prognosis for patients with necrotic lung cancer."

In summary, the clinical implications of necrotic lung cancer emphasize the importance of accurate diagnosis and recognition of symptoms. Imaging techniques and histopathological evaluation contribute significantly to understanding and managing this condition.

Challenges in Treatment Options

The treatment of necrotic lung cancer presents unique challenges that significantly impact patient outcomes. Understanding these challenges is vital for developing effective management strategies. Tumor necrosis, often a consequence of inadequate blood supply and other factors, complicates treatment choices. It can alter tumor biology, leading to resistance against standard therapies. These complexities necessitate a tailored approach to treatment, considering the specific characteristics of the tumor and the overall health of the patient.

Surgical Approaches

Surgery remains a primary treatment option for localized lung cancer. However, in cases of necrotic tumors, the approach must be judicious. Surgical resection can be more complicated due to necrosis affecting the tumor's integrity and the surrounding healthy tissue. Surgeons must carefully evaluate the extent of necrosis before proceeding. The decision depends on accessibility and whether the necrosis has impacted neighboring organs.

Resection vs. Lobectomy: The choice between resection and lobectomy varies with tumor size and necrosis extent.
Minimally Invasive Techniques: Techniques like video-assisted thoracoscopic surgery (VATS) offer reduced recovery time but come with their own set of challenges in necrotic cases.
Oncological Outcomes: The success of surgical options heavily relies on accurate preoperative imaging and diagnostics to determine necrosis levels.

In summary, while surgical options exist, careful assessment and planning are essential for favorable results.

Chemotherapy and Targeted Therapies

Chemotherapy is a cornerstone in the management of lung cancer. However, the presence of necrosis creates significant treatment hurdles. Tumor necrosis may signal a lack of effective blood supply, limiting the delivery of chemotherapeutic agents to the tumor site. This leads health care providers to consider alternative strategies.

Combination Therapies: Combining chemotherapy with targeted therapies may enhance efficacy. Targeted therapies focus on specific mutations within tumors, offering a potential advantage over traditional chemotherapy alone.
Resistance Mechanisms: Necrotic sieves alter tumor biology, leading to acquired resistance. This necessitates ongoing research to identify effective drug combinations and sequencing.
Patient Monitoring: Close monitoring of patient response is critical to adjust treatment plans as needed.

Adapting chemotherapy regimens for necrotic lung cancer thus involves intricate planning for better therapeutic outcomes.

Immunotherapy and its Limitations

Immunotherapy has emerged as a promising strategy in lung cancer treatment, particularly for advanced stages. Still, the effectiveness of immunotherapy in necrotic lung tumors remains uncertain. Understanding the limitations is crucial for setting realistic treatment expectations.

Immune Environment: Necrosis can create a hostile microenvironment, hindering immune response. The presence of necrotic cells may disrupt the effectiveness of immunotherapeutic agents such as checkpoints inhibitors.
Biomarkers for Response: Research is ongoing to identify biomarkers that predict response to immunotherapy in necrotic tumors. These biomarkers can help tailor treatments for improved effectiveness.
Potential Side Effects: As with any treatment, immunotherapy comes with potential adverse effects. In necrotic lung cancer, managing these effects is vital as they might overlap with symptoms caused by the disease itself.

To effectively manage necrotic lung cancer, a robust understanding of current treatment challenges and options is necessary for health care professionals. The ability to adapt treatment plans based on tumor characteristics and patient response is crucial for improving outcomes in this complex condition.

Prognostic Factors for Necrotic Lung Cancer

Infographic on treatment challenges in necrotic lung cancer

Understanding the prognostic factors in necrotic lung cancer is crucial for predicting patient outcomes and tailoring treatment strategies. Numerous elements play significant roles in determining how the disease progresses and how patients respond to various therapies. Knowing these factors can aid healthcare professionals in making informed clinical decisions. This section will discuss two main prognostic factors: tumor characteristics and patient demographics.

Tumor Characteristics

The characteristics of the tumors help to predict the likely progression of necrotic lung cancer. Several specific traits warrant attention:

Tumor Size: Larger tumors generally correlate with worse outcomes. They may show more necrosis, which can indicate aggressive behavior.
Histological Type: Different histology types, such as adenocarcinoma or squamous cell carcinoma, vary significantly in their behavior and response to treatment. Understanding these types can inform prognosis.
Degree of Necrosis: A high degree of necrosis within a tumor can signify advanced disease and often correlates with worse patient outcomes.
Vascular Invasion: If tumors exhibit vascular invasion, this can hint at metastatic potential, thus impacting prognosis negatively.

In practice, assessing these characteristics allows clinicians to stratify patients based on risk. Those with unfavorable characteristics may need more aggressive or alternative treatment plans. This stratification can profoundly affect survival rates and quality of life.

Patient Demographics

Demographic factors play another essential role in prognosis for patients with necrotic lung cancer. Significant aspects to consider include:

Age: Older patients often have more comorbidities that can complicate treatment, impacting survival and overall prognosis.
Gender: Some studies suggest that males may have poorer prognostic outcomes compared to females, possibly due to biological differences and smoking rates.
Ethnicity: Varying genetic backgrounds can influence tumor behavior and treatment response, requiring customized approaches based on a patient's ethnic background.
Socioeconomic Status: Patients from lower socioeconomic statuses may face barriers to accessing care, which can adversely affect survival.

It is essential to adopt a holistic approach when evaluating prognostic factors, as both tumor characteristics and patient demographics can significantly impact treatment strategies and outcomes.

Understanding these prognostic factors forms a foundation for better management of necrotic lung cancer, allowing for more personalized care. Overall, the interplay between these factors emphasizes the need for a comprehensive approach to patient evaluation.

Current Research Trends

Understanding the current research trends in necrotic lung cancer is crucial for advancing diagnostic and therapeutic strategies. This area of research is expanding rapidly, driven by the need to address the unique challenges posed by necrosis in tumor behavior. The integration of novel techniques and biomarkers into clinical practice holds significant promise for improving patient outcomes.

Emerging Biomarkers

Emerging biomarkers provide insights into the biological behavior of necrotic lung tumors. Researchers are actively investigating specific markers that may indicate the presence and severity of necrosis within lung cancer. For instance, proteins released during cell death might serve as indicators for diagnosing necrotic tumors. Additionally, genomic profiling is being employed to identify mutations that correlate with tumor necrosis. These biomarkers not only enhance diagnostic precision but also allow for personalized treatment approaches. Early identification of patients with necrotic lung cancer through biomarker analysis can lead to more tailored therapies and better prognoses.

"Biomarkers are revolutionizing the way we understand cancer."

Aisha Thompson, Oncologist

Benefits of Emerging Biomarkers

Increased diagnostic accuracy: Biomarkers enhance specificity and sensitivity in detection.
Personalized treatments: Understanding individual tumor characteristics allows for customized therapy regimens.
Predictive power: Certain biomarkers may predict treatment responses or disease progression.

Ongoing Clinical Trials

Ongoing clinical trials represent a critical avenue for exploring new treatments and therapies specifically designed for necrotic lung cancer. These trials often focus on innovative approaches that address the unique challenges of necrosis, such as limited tumor perfusion and hypoxic conditions. Researchers are evaluating a variety of interventions including novel chemotherapy regimens, combination therapies, and targeted agents aimed at the necrotic tumor microenvironment.

In addition to traditional endpoints, some trials are incorporating biomarkers to better understand treatment efficacy. This dual approach is essential for validating the clinical significance of various biomarkers and ensuring that therapeutic strategies are effective for patients with necrotic tumors.

Key Considerations for Clinical Trials

Ethical implications: Informed consent and patient safety must always be prioritized.
Diversity in population: Inclusion of diverse patient demographics is vital for generalizability of results.
Long-term follow-ups: Assessing prolonged outcomes can provide deeper insights into treatment impacts.

Current research trends reveal a dynamic shift towards more precise and effective management strategies for necrotic lung cancer. As the field evolves, the importance of emerging biomarkers and ongoing clinical trials becomes increasingly evident, paving the way for innovative solutions to long-standing treatment challenges.

Case Studies in Necrotic Lung Cancer

Case studies play a pivotal role in understanding necrotic lung cancer. They provide real-world insights into the behavior of the disease, treatment responses, and patient outcomes. These documented instances often highlight unique presentations and complications that arise from the necrotic nature of lung tumors. They can guide clinical decision-making and enhance the overall understanding of this complex condition. Furthermore, case studies often discuss rare occurrences, which could steer further research or highlight the need for novel treatment approaches.

Notable Patient Cases

There have been several notable patient cases that have shaped the understanding of necrotic lung cancer. One case involved a 67-year-old man diagnosed with advanced lung cancer. His tumor exhibited extensive necrosis, leading to complications such as hemoptysis and pneumothorax. Surgical intervention was deemed high-risk; therefore, chemotherapy was prioritized. The outcomes demonstrated that while effective in reducing tumor size, chemotherapeutic agents produced significant side effects, impacting the patient's quality of life.

Another compelling case is that of a 45-year-old woman with a large necrotic mass localized in the right lung. The imaging studies revealed significant cavitation within the tumor. Initially misdiagnosed as a lung abscess, further investigation revealed the necrotic malignancy. This case illustrates the importance of differential diagnosis and showcases the pitfall of assuming that necrosis is always indicative of benign processes.

Future directions in targeted therapies for lung cancer

Lessons from Clinical Outcomes

The lessons garnered from these clinical outcomes are profound and multifaceted. They underscore the importance of a thorough diagnostic process that considers necrosis as a potential marker of malignancy rather than a simple indicator of infection.

Moreover, patient management requires a nuanced approach that weighs the benefits of aggressive treatment against potential quality of life detriments. For instance, careful symptom management is crucial in cases where aggressive treatment might lead to more significant complications without clear survival benefits. Additionally, these cases highlight the necessity for interdisciplinary collaboration among oncologists, radiologists, and palliative care teams.

In summary, case studies in necrotic lung cancer not only shed light on individual patient experiences but also carry broader implications for clinical practice and research. They provide invaluable lessons that can help refine treatment strategies and improve patient outcomes.

Patient Management Strategies

Patient management strategies are critical in the context of necrotic lung cancer. Due to the unique nature of this condition, patients often experience complex symptomatology due to both the cancer itself and the effects of necrosis on lung tissue. Effective management is not just about extending life but also ensuring a better quality of life. Understanding how to navigate the patient journey is essential for healthcare providers.

Palliative Care Approaches

Palliative care plays a significant role for patients diagnosed with necrotic lung cancer. This approach focuses on providing relief from symptoms and improving the overall quality of life for patients. Here are some key elements:

Symptom Management: Palliative care teams work to control pain, breathlessness, cough, and fatigue. Utilizing medications such as opioids for pain relief and bronchodilators for dyspnea can significantly alleviate patient suffering.
Emotional Support: Counseling and psychological support are essential, since emotional distress is common among cancer patients. A trained team can help patients and families cope with the diagnosis and its implications.
Coordination of Care: Palliative care teams act as an intermediary between various healthcare providers, ensuring all aspects of patient care are considered. This coordination can help avoid fragmented care, enhancing treatment journey efficiency.

"Palliative care is not synonymous with end-of-life care; it can begin at diagnosis and alongside curative treatment."

Supportive Treatments

Supportive treatments are essential in addressing the multifaceted needs of patients suffering from necrotic lung cancer. These treatments complement primary therapies by targeting symptoms and enhancing overall well-being. Major components include:

Nutritional Support: Malnutrition is prevalent in cancer patients due to loss of appetite and metabolic changes. Dietitians can develop tailored nutrition plans to help patients maintain or regain strength.
Physical Therapy: Engaging patients in physical therapy can improve mobility and reduce fatigue, especially during and after treatment. A personalized exercise plan can encourage better respiratory function.
Alternative Therapies: Some patients may benefit from integrative therapies like acupuncture or mindfulness practices. These methods can help in managing stress and improving emotional well-being.

Quality of Life Considerations

Quality of life is a crucial aspect of healthcare, especially when dealing with necrotic lung cancer. This malignant condition not only affects physical health but also has profound implications for individuals' emotional and social wellbeing. Understanding these elements can support patients in managing their condition effectively while maintaining a better quality of life.

Patients with necrotic lung cancer often experience complex challenges that impact their daily lives. The physical symptoms, including pain, fatigue, and respiratory difficulties, can significantly hinder their daily activities. Additionally, psychological factors such as anxiety and depression can emerge due to the stress of diagnosis and subsequent treatment. Therefore, it is vital to acknowledge how these aspects intertwine and affect overall health.

Psychosocial Support

Psychosocial support emerges as an essential component of care for patients with necrotic lung cancer. This support includes psychological counseling, social services, and community resources. Addressing the emotional needs of patients can enhance their coping mechanisms, ultimately improving their overall quality of life.

Counseling Services: Many patients benefit from professional psychological support to navigate their feelings and fears surrounding their diagnosis. Therapeutic sessions can provide patients the outlet needed to express their concerns and explore stress management techniques.
Support Groups: Engaging with peers facing similar challenges can be empowering. Support groups facilitate shared experiences and provide emotional comfort. In these environments, patients can learn coping strategies and develop a sense of community.
Educational Resources: Providing information about the disease and treatment options can alleviate some anxiety. Knowledge allows patients to make informed decisions about their care, fostering a sense of control.

"Psychosocial interventions can lead to a significant reduction in anxiety and depression among cancer patients, which is crucial for enhancing their overall experience with the disease."

Managing Symptoms and Side Effects

Effective management of symptoms and side effects is vital for enhancing quality of life in patients with necrotic lung cancer. Symptom control not only alleviates discomfort but also helps patients engage more fully in their daily activities.

Pain Management: Pain can be a predominant symptom. Utilizing opioids and adjunctive therapies, such as physical therapy and acupuncture, can facilitate better control over pain levels.
Managing Respiratory Issues: Breathing difficulties are often present. Interventions such as bronchodilators, corticosteroids, and oxygen therapy can improve lung function, enhancing physical capability.
Nutritional Support: Cancer and its treatments can lead to weight loss and nutritional deficiencies. Dietary counseling and supplementation can help maintain strength and energy levels.
Fatigue Management: Chronic fatigue is common but can be mitigated through structured physical activities and energy conservation techniques. A tailored exercise program can help improve stamina while reducing fatigue.

Focusing on these aspects contributes greatly to the overall treatment approach, promoting not just survival but also living well during the journey of combating necrotic lung cancer.

Future Perspectives in Necrotic Lung Cancer Research

Understanding the future of necrotic lung cancer research is critical. As science progresses, the need for innovative approaches becomes even more pronounced. Researchers are focusing on discovering solutions to the challenges posed by necrosis in lung cancer. This is important because necrotic tissue often complicates treatment options and negatively affects patient outcomes. Recognizing the pathways that govern necrosis can ultimately lead to better therapeutic strategies. Such advancements have the potential to enhance patient diagnosis, management, and prognosis.

Innovative Diagnostic Techniques

Emerging diagnostic techniques are expected to revolutionize how necrotic lung cancer is identified and managed. Advanced imaging modalities, such as positron emission tomography (PET) combined with computed tomography (CT), allow for more precise evaluation of tumor characteristics and necrotic areas. Also, liquid biopsies are gaining attention as a non-invasive method to analyze tumor-derived components in blood. These methods can provide unique insights into tumor heterogeneity and treatment resistance, which is a significant concern in lung cancer management.

In addition, techniques such as organoid culture now enable researchers to study cancer cells in a lab environment that closely mimics the human body. This could lead to better understanding of tumor behavior and response to therapies before initiating treatment in patients. Integrating these innovative approaches may significantly enhance early detection and personalized treatment plans for necrotic lung cancer.

Advancements in Therapeutics

Therapeutic advancements are vital in addressing the treatment challenges related to necrotic lung cancer. One promising area is the development of targeted therapies aimed at specific molecular pathways involved in tumor necrosis and survival, thereby providing a more personalized treatment method. For instance, inhibitors that target the vascular endothelial growth factor (VEGF) have shown to modify the tumor microenvironment, possibly reducing necrosis and improving treatment efficacy.

Immunotherapy, particularly checkpoint inhibitors, also marks a shift in lung cancer treatment. Identifying suitable biomarkers for patient selection can enhance the effectiveness of these therapies against necrotic tumors. Additionally, approaches like oncolytic virus therapy are being explored. This method utilizes modified viruses to selectively kill cancer cells while sparing normal tissues, including necrotic ones, providing an innovative way to manage tumor growth.

The continuous evolution of combination therapies offer another avenue for treatment. By integrating conventional chemotherapy with advanced modalities like molecular therapies or immunotherapies, clinicians can achieve more robust responses, especially in challenging cases of necrotic lung cancer.

Have More Awesome Articles:

The Role of Coenzyme Q10 in Kidney Disease: An Analytical Review Introduction